药物发现和开发的基本原则 1336条(本栏目收费,不能显示细节,电话15274084725)
permeability. See Permeability 0
plasma protein binding, 268–270,269f–270f 270
solubility, 250–254, 250f–254f 254
transporters, 266–268, 268f 268
Acetylcholine-binding protein (AChBP),121, 122f 122
α1-Acid glycoprotein (AGP), 268–269 269
Acquired immune deficiency syndrome (AIDS), 1 1
diagnoses annual report, 506–507, 507f 507
Active transport mode, 255, 255f 255
Adenosine-5′-triphosphate (ATP), 99–101,102f 102
ADME. See Absorption, distribution, 0
metabolism, and excretion (ADME) 0
Aequorin-based assay systems, 178–180 180
Agonists, 112–114, 113f, 150, 150f 150
CFP fluorescence, 170–171 171
GPCR activation, 174–175, 174f 174
μ-opioid receptor, 16–18, 17f, 209–210,517–518 518
Allosteric inhibitors, 103f, 104 104
Ames assay, 356–357, 357f 357
γ-Aminobutyric acid (GABA), 122–123, 123f 123
Amiodarone, 116, 116f 116
Amplified luminescent proximity 0
homogeneous assay (AlphaScreen™), 175–177,175f–177f 177
Amyotrophic lateral sclerosis (ALS), 15,310–311, 346 346
Anacetrapib (MK-0859), 12, 12f 12
Animal models, disease states 0
cardiovascular disease animal model, 323 323